Pancreatic Cancer Research

ResearcherChristian-Albrechts-Universität zu KielActive in the last 2 years

Daniela Wesch

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6509-208X; OpenAlex author ID A5052373782. Sources: OpenAlex.

Their work

Papers
14 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
2
Collaborators
29
Papers, trials and grants by year

2014: 3 papers · 2015: 2 papers · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: none · 2025: none · 2026: 2 papers

Papers 14

  1. Novel L1CAM-antibody drug conjugates exert potent anti-tumor activity in preclinical models of even advanced pancreatic cancer. Co-author DOI 10.1016/j.biopha.2026.119257↗
  2. L1CAMxCD3 bispecific antibodies exert potent anti-tumor effects in preclinical pancreatic cancer models considering the complex tumor stroma Co-author DOI 10.64898/2026.08.10.743835↗
  3. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fimmu.2023.1157397↗
  4. Hepatic myofibroblasts exert immunosuppressive effects independent of the immune checkpoint regulator PD-L1 in liver metastasis of pancreatic ductal adenocarci… Co-author DOI 10.3389/fonc.2023.1160824↗
  5. Initiation of Pancreatic Cancer: The Interplay of Hyperglycemia and Macrophages Promotes the Acquisition of Malignancy-Associated Properties in Pancreatic Duct… Co-author DOI 10.3390/ijms22105086↗
  6. Galectin-3 Released by Pancreatic Ductal Adenocarcinoma Suppresses γδ T Cell Proliferation but Not Their Cytotoxicity. Last author DOI 10.3389/fimmu.2020.01328↗
  7. Influence of Indoleamine-2,3-Dioxygenase and Its Metabolite Kynurenine on γδ T Cell Cytotoxicity against Ductal Pancreatic Adenocarcinoma Cells. Last author DOI 10.3390/cells9051140↗
  8. POLE Score: a comprehensive profiling of programmed death 1 ligand 1 expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.26705↗
  9. Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1016/j.pan.2016.07.008↗
  10. CD4+ T cells potently induce epithelial-mesenchymal-transition in premalignant and malignant pancreatic ductal epithelial cells-novel implications of CD4+ T ce… Co-author DOI 10.1080/2162402x.2014.1000083↗
  11. Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against γδ T cell cytotoxicity. Last author DOI 10.4161/2162402x.2014.988460↗
  12. L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression. Co-author DOI 10.1016/j.molonc.2014.03.001↗
  13. Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells. Last author DOI 10.1158/0008-5472.can-13-0675↗
  14. Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0094357↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Susanne Sebens · 13 shared papers, 2014–2026 · strength 1.40
  2. Christoph Röcken · 10 shared papers, 2014–2026 · strength 1.09
  3. Tina Daunke · 4 shared papers, 2021–2026 · strength 0.70
  4. Anna Maxi Wandmacher · 3 shared papers, 2023–2026 · strength 0.63
  5. H. Schäfer · 6 shared papers, 2014–2023 · strength 0.58
  6. Silje Beckinger · 3 shared papers, 2023–2026 · strength 0.57
  7. Sascha Rahn · 4 shared papers, 2019–2023 · strength 0.56
  8. Hans‐Heinrich Oberg · 7 shared papers, 2014–2020 · strength 0.50
  9. Rüdiger Braun · 2 shared papers, 2026 · strength 0.47
  10. Anne‐Sophie Mehdorn · 2 shared papers, 2026 · strength 0.47
  11. Annika Bräuer · 2 shared papers, 2026 · strength 0.47
  12. Daniel Gonnermann · 4 shared papers, 2015–2020 · strength 0.34
  13. Steffen Markus Heckl · 2 shared papers, 2023 · strength 0.34
  14. Rainer Lothar Heuchel · 1 shared paper, 2026 · strength 0.24
  15. Jan-Paul Gundlach · 1 shared paper, 2026 · strength 0.24
  16. Benjamin Heckelmann · 1 shared paper, 2026 · strength 0.23
  17. Lisa Goebel · 4 shared papers, 2014–2019 · strength 0.21
  18. Ole Helm · 3 shared papers, 2014–2019 · strength 0.17
  19. Christian P. Pilarsky · 1 shared paper, 2023 · strength 0.16
  20. Lilli Otto · 1 shared paper, 2021 · strength 0.13
  21. Evelin Grage‐Griebenow · 3 shared papers, 2014–2016 · strength 0.13
  22. Hannah Jonescheit · 1 shared paper, 2020 · strength 0.12
  23. Bence Sipos · 2 shared papers, 2014–2015 · strength 0.08
  24. Lennart Lenk · 1 shared paper, 2015 · strength 0.04
  25. Hendrik Ungefroren · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.